Behavioural Pharmacology
October 13, 2015
Filip Tylš, Tomáš Páleníček, Lukáš Kadeřábek et al.
86 citations
Psilocybin has recently attracted a great deal of attention as a clinical research and therapeutic tool. The aim of this paper is to bridge two major knowledge gaps regarding its behavioural pharmacology – sex differences and the underlying receptor mechanisms. We used psilocin (0.25, 1 and 4 mg/kg), an active metabolite of psilocybin, in two behavioural paradigms – the open-field test and...
Drug Testing and Analysis
October 12, 2015
Simon D. Brandt, Pierce V. Kavanagh, Folker Westphal et al.
79 citations
1‐Propionyl‐ d ‐lysergic acid diethylamide hemitartrate (1P‐LSD) has become available as a ‘research chemical’ in the form of blotters and powdered material. This non‐controlled derivative of d ‐lysergic acid diethylamide (LSD) has previously not been described in the published literature despite being closely related to 1‐acetyl‐LSD (ALD‐52), which was developed in the 1950s. This study...
Substance Abuse
October 1, 2015
Kara S. Bagot, Robert Milin, Yifrah Kaminer
Background: It is important to evaluate the impact of cannabis use on onset and course of psychotic illness, as the increasing number of novice cannabis users may translate into a greater public health burden. This study aims to examine the relationship between adolescent onset of regular marijuana use and age of onset of prodromal symptoms, or first episode psychosis, and the manifestation of...
Neurobiology of Disease
October 2015
Michael D Ballinger, Atsushi Saito, Bagrat Abazyan et al.
Cannabis is an increasingly popular and controversial drug used worldwide. Cannabis use often begins during adolescence, a highly susceptible period for environmental stimuli to alter functional and structural organization of the developing brain. Given that adolescence is a critical time for the emergence of mental illnesses before full-onset in early adulthood, it is particularly important to...
Experimental and Clinical Psychopharmacology
October 2015
Jane Metrik, Elizabeth R Aston, Christopher W Kahler et al.
Marijuana produces acute increases in positive subjective effects and decreased reactivity to negative affective stimuli, though may also acutely induce anxiety. Implicit attentional and evaluative processes may explicate marijuana's ability to acutely increase positive and negative emotions. This within-subjects study examined whether smoked marijuana with 2.7-3.0% delta-9-tetrahydrocannabinol...
JAACAP Connect
October 1, 2015
Steven Storage, Yelizaveta Sher
A 17-year-old male with a history of attention-deficit/hyperactivity disorder (ADHD) was brought by the police to the emergency room from his school for bizarre behavior. According to the reports, the patient had been observed talking to himself during class, laughing inappropriately, and making odd statements. The patient initially denied illicit substance use, and his urine toxicology and...
American Journal of Psychiatry
October 1, 2015
D. Jeffrey Newport, Linda L. Carpenter, William M. Mcdonald et al.
594 citations
OBJECTIVE: The authors conducted a systematic review and meta-analysis of ketamine and other N-methyl-d-aspartate (NMDA) receptor antagonists in the treatment of major depression. METHOD: Searches of MEDLINE, PsycINFO, and other databases were conducted for placebo-controlled, double-blind, randomized clinical trials of NMDA antagonists in the treatment of depression. Primary outcomes were...
Behavioural Brain Research
September 15, 2015
Natashia Swalve, Scott T Barrett, Rick A Bevins et al.
Nicotine is a widely-abused drug, yet its primary reinforcing effect does not seem potent as other stimulants such as cocaine. Recent research on the contributing factors toward chronic use of nicotine-containing products has implicated the role of reinforcement-enhancing effects of nicotine. The present study investigates whether phencyclidine (PCP) may also possess a reinforcement-enhancement...
Translational Psychiatry
September 15, 2015
Matthew B Young, Raül Andero, Kerry J. Ressler et al.
137 citations
Abstract Acutely administered 3,4-methylenedioxymethamphetamine (MDMA, ‘ecstasy’) has been proposed to have long-term positive effects on post-traumatic stress disorder (PTSD) symptoms when combined with psychotherapy. No preclinical data support a mechanistic basis for these claims. Given the persistent nature of psychotherapeutic gains facilitated by MDMA, we hypothesized that MDMA improves...
Journal of Medical Case Reports
September 11, 2015
Anders Håkansson, Björn Axel Johansson
10 citations
INTRODUCTION: Adolescents with psychoses usually have full recovery from their first psychotic episode, but the first relapse often arises within 2 years of the first episode. Cannabis-related psychoses are difficult to distinguish from schizophrenic psychoses. Here, we describe a particularly severe clinical case, with a first psychotic episode occurring after heavy cannabis smoking, an...